Table I.
Clinical and pathological information of serum samples used for training and validation assays. B, Bellvitge University Hospital, Institut Catalá d́Oncología (Barcelona, Spain); PH, Puerta de Hierro Hospital (Madrid, Spain), C, Cabueñes Hospital (Gijón, Spain)
| Gender |
Dukes stage |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number (n) | Hospital | Age average (years) | Age range (years) | Male | Female | A | B | C | D | ||
| Total | CRC | 65 | 69.7 | 41–91 | 67.7% | 33.3% | 19% | 22% | 29% | 30% | |
| Controls | 118 | 68.4 | 26–89 | 61.5% | 38.5% | – | – | – | – | ||
| Microarray screening | CRC | 15 | B | 66.2 | 54–82 | 73% | 27% | 40% | 20% | 20% | 20% |
| Healthy | 15 | B | 63.5 | 39–89 | 60% | 40% | – | – | – | – | |
| Validation | CRC | 50 | B, PH | 70.8 | 41–91 | 66% | 34% | 12% | 22% | 32% | 34% |
| Controls | 103 | B, PH, C | 59.2 | 26–89 | 51% | 49% | – | – | – | – | |
| Healthy | 46 | B, PH, C | 59.6 | 34–89 | 63% | 37% | – | – | – | – | |
| CRC familiar antecedents | 10 | C | 49.4 | 26–73 | 25% | 75% | – | – | – | – | |
| Ulcerative colitis | 2 | C | 39 | 28–49 | 50% | 50% | – | – | – | – | |
| Hyperplasic polyp | 2 | C | 67 | 61–73 | 50% | 50% | – | – | – | – | |
| Other tumors | |||||||||||
| Bladder cancer | 11 | B | 67.7 | 58–78 | 64% | 36% | – | – | – | – | |
| Breast cancer | 8 | B | 52 | 30–66 | 0% | 100% | – | – | – | – | |
| Lung cancer | 8 | B | 63 | 55–77 | 75% | 25% | – | – | – | – | |
| Pancreas cancer | 8 | B | 65 | 37–74 | 62% | 38% | – | – | – | – | |
| Stomach cancer | 8 | B | 62 | 37–80 | 25% | 75% | – | – | – | – | |